Dysgerminoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Clinical Trials

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Conditions:   Germ Cell Tumor;   Nonseminomatous Germ Cell Tumor;   Seminoma;   Germinomatous Germ Cell Tumor;   Dysgerminoma;   Pineal Germ Cell Tumor Interventions:   Drug: Durvalumab;   Drug: Tremelimumab Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting - verified May 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 16, 2017 Category: Research Source Type: clinical trials